A new research study at Rush University Medical Center and Northwestern Medicine is testing whether a new investigational treatment can slow the memory loss caused by Alzheimer’s disease.
The study will include men and women ages 65 to 85 who have normal thinking and memory function but who may be at risk for developing Alzheimer’s disease (AD) memory loss sometime in the future.
The purpose of the research study, called the Anti-Amyloid Treatment in Asymptomatic Alzheimer’s study (the “A4 study” for short), is to test whether a new investigational drug, called an amyloid antibody, can slow memory loss caused by Alzheimer’s disease.
Amyloid is a protein normally produced in the brain that can build up in older people, forming amyloid plaque deposits. Scientists believe this buildup of deposits may play a key role in the eventual development of Alzheimer’s disease-related memory loss and dementia. The overall goal of the A4 study is to test whether decreasing amyloid with antibody investigational drug can help slow the memory loss associated with amyloid buildup in some people.
Swim Across America events have raised roughly $50 million for cancer research nationwide.
As many as 10 former Olympians, along with scores of others, will participate in the Swim Across America (SAA) fundraiser Saturday, July 26, at Ohio Street Beach in Chicago. It is SAA’s 21st annual Chicago event.
Swim Across America is a national nonprofit organization dedicated to raising money for cancer research, prevention and treatment through swimming events across the country.
The fundraiser benefits the Rush University Cancer Center, which comprises all of the clinical, research and educational efforts at Rush University Medical Center. SAA is aiming to top the more than $400,000 raised at last year’s event.
“What Swim Across America has achieved in Chicago and around the country is incredible,” said David McClellan, SAA Chicago event director. “We always set our sights high, but we expect a record-breaking 2014 event in hopes of funding groundbreaking cancer research at Rush.”
Read the news release.
Robin Voigt, PhD
A disruption of circadian rhythms, when combined with a high-fat, high-sugar diet, may contribute to inflammatory bowel disease and other harmful conditions, according to a recent study conducted by researchers at Rush University Medical Center. The study is online at the peer-reviewed, open-access journal, PLOS ONE.
“Circadian rhythms, which impose a 24-hour cycle on our bodies, are different from sleep patterns,” said Robin M. Voigt, PhD, assistant professor at Rush Medical College and first author of the study. “Sleep is a consequence of circadian rhythms,” Voigt said.
While circadian rhythm disruption may be common among some, the research suggests that it may be contributing to a host of diseases that may be prevented by regulating things such as sleep/wake patterns and times of eating to help prevent circadian rhythm disruption. Including prebiotics or probiotics in the diet can also help normalize the effects of circadian rhythm disruption on the intestinal microbiota to reduce the presence of inflammation.
“It’s something that needs to be addressed — not something people need to be very concerned about, but aware. If you have some of these other risk factors, like a high-fat, high-sugar diet,” or a genetic tendency toward disruption in circadian rhythms, “take precautions, watch your diet, take pre- and probiotics, monitor your health, be vigilant,” Voigt said.
A new study by researchers at Rush University Medical Center reviews research that suggests that the risk for developing Alzheimer’s disease among older African-Americans may be two to three times greater than in the non-Hispanic white population and that they differ from the non-Hispanic white population in risk factors and disease manifestation. The study results are published in the April issue of Health Affairs.
“The older African-American population is growing at a rapid pace, and the burden of aging-related cognitive impairment and Alzheimer’s disease will continue to present a tremendous challenge,” said Lisa Barnes, PhD. “This study highlights the importance of research among minority groups within the communities in which hospitals serve.”
Barnes is the primary author and director of the Rush Center of Excellence on Disparities in HIV and Aging in the Rush Alzheimer’s Disease Center, and professor of Neurological Sciences and Behavioral Sciences at Rush University Medical Center.
“The lack of high-quality biologic data on large numbers of racial and ethnic minorities poses barriers to progress in understanding whether the mechanisms and processes of Alzheimer’s disease operate the same or differently in racial and ethnic minorities and, if so, how, particularly in the high-risk African-American population,” said Barnes.
In 2010, the U.S. Census Bureau indicated that 20 percent of the population ages 65 and older was a racial or ethnic minority member. Current projections suggest that by 2050, 42 percent of the nation’s older adults will be members of minority groups. Among those ages 85 and older, 33 percent are projected to be a minority.
Read the entire release for more information on the study.
Researchers at Rush have identified the underlying mechanism of calcium-triggered cardiac arrhythmias, or irregular heartbeats. The discovery, described in the Jan. 19 issue of Nature Medicine, has major implications for the development of molecularly designed drugs specifically targeted at this form of arrhythmia.
The study was led by Wayne Chen, PhD, professor of molecular biophysics and physiology at Rush and professor of physiology and biochemistry at the University of Calgary-Libin Institute. Michael Fill, PhD, professor of molecular biophysics and physiology at Rush, collaborated on the research.
Cardiac arrhythmias can cause dizziness and fainting, or in severe cases, sudden death. While many factors, including genetics, contribute to the development of arrhythmias, research has shown that a common cause of cardiac arrhythmias is calcium overload. Calcium overload disrupts the finely controlled electrical activity governing contraction of heart muscle.
Calcium is stored inside cardiac cells, much like skeletal muscle cells, in preparation for contraction. The protein responsible for release of calcium is known as the cardiac ryanodine receptor (RyR2), or the calcium release channel, which acts like a safety valve that prevents calcium overload.
Read the news release.
A newly-developed, “designer” dietary fiber with an added potential prebiotic effect may eliminate the side effects of current treatment for irritable bowel syndrome (IBS), which affects 10 to 20 percent of the population, disproportionately women.
The collaboration between a gastroenterologist at Rush and a carbohydrate chemist at Purdue University led to the development of the new product, a natural starch derived from a mixture of seaweed and starch in which the release of starch fiber in the gastrointestinal tract can be delayed, slowed and controlled to occur in the colon, rather than in the stomach and upper intestine.
“This new product prevents the discomfort and bloating associated with current fiber therapies, while getting our new fiber into the colon and specifically distal colon where traditional fiber products typically do not reach and where many diseases of colon-like cancers develop,” said Dr. Ece Mutlu, principal investigator the phase II trial that will begin at Rush in January 2014. “This can provide an effective treatment for IBS, decrease the risk of colon cancer and possibly inflammatory diseases like colitis,” she added. The study seeks 200 people who have been diagnosed with IBS and constipation.
In an earlier Phase I study with 60 patients suffering from constipation, the newly designed fiber was shown to be safe, better tolerated and with fewer side effects than currently available fiber treatments for constipation, and it had a positive effect on intestinal microbiota composition by promoting the growth of “healthy” bacteria in the colon.
Read the news release.
Dr. Lydia Usha, director of the Rush Inherited Susceptibility to Cancer (RISC) program at Rush, is currently investigating genetic causes of cancer in patients who tested negative for the BRCA1 and BRCA2 genetic mutations but still developed breast or ovarian cancer and have a known mutation in one of these genes in the family.
The results may help explain why patients who test negative for a genetic predisposition to cancer may still develop cancer. Usha is examining the idea that certain people have the familial BRCA mutation in some tissues, but not in their blood. She hypothesizes that these patients have had BRCA-positive chimeric cells in their body since birth, making these cells more susceptible to developing cancer. Usha and her team are recruiting patients and testing their cancer tissue for the familial mutation.
“This is important because we know that some drugs are more effective in treating patients who have breast and ovarian cancers with these specific mutations,” Usha said.
Read the entire story.